Growth Hormone Fragment 176-191 · Lipolytic Peptide · Protocol Guide
AOD-9604: The Honest Fat-Loss Peptide Guide
AOD-9604 is a fragment of human growth hormone built to keep GH's fat-burning effect and drop everything else. The rodent lipolysis data is real. The human story is harder: its largest obesity trial did not beat placebo, and development was shelved in 2007. This guide draws that line clearly.
- FDA Status
- Investigational, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: AOD-9604's preclinical fat-loss data in mice and rats is genuine and reproducible. Its human record is not flattering: the largest obesity trial, a 534-subject Phase 2b, failed to show clinically meaningful weight loss over placebo, and the developer halted the program in 2007. We say where the animal data stops and where the human data falls short, rather than selling past it.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 8, 2026.On this page
Section 01
What AOD-9604 Actually Is
AOD-9604 is a synthetic peptide built from the tail end of human growth hormone. Specifically, it copies the 176-191 region of the growth hormone molecule, the segment that researchers tied to fat metabolism, with a small stabilizing modification at the front. The acronym stands for Anti-Obesity Drug, the name given to it by Metabolic Pharmaceuticals, the Australian company that developed it.
The idea behind it is clean and worth understanding. Full growth hormone burns fat, but it does many other things at the same time: it raises blood sugar, can worsen insulin sensitivity, and drives broad growth signaling through IGF-1. AOD-9604 was designed to keep the fat-burning part and drop the rest. In the lab, that separation held up. The fragment increased lipolysis without binding the growth hormone receptor and without the cell proliferation that full growth hormone produces.
What AOD-9604 is not is just as important. It is not growth hormone. It does not raise IGF-1, does not build muscle, and does not produce the systemic growth effects of a GH secretagogue. Its job, by design, is narrow: nudge fat cells toward releasing and oxidizing fat. Whether that narrow job translates into real weight loss in humans is the harder question, and the one this guide does not gloss over.
176-191
The C-terminal region of growth hormone this fragment copies
534
Subjects in the Phase 2b obesity trial that missed its primary endpoint
2007
Year the developer halted the obesity development program
503A
Pathway for U.S. compounded access under physician prescription
Section 02
Who It Is Actually For
Because the strongest human trial was negative, the honest framing of fit matters more here than usual. AOD-9604 is best understood as an adjunct with a clean safety record and a narrow, unproven fat-metabolism rationale, not as a standalone weight-loss drug.
| Profile | Primary Motivation | Evidence Basis | Fit |
|---|---|---|---|
| Adjunct to Diet, Training, or a GLP-1 | Modest metabolic support inside a structured fat-loss plan | Mechanistically plausible, no proven additive human benefit. Use realistic expectations. | Adjunct Only |
| Cautious Body-Composition User | Targeted fat support without GH side effects | Animal lipolysis data plus a long human safety record. Efficacy in humans is unproven. | Exploratory |
| Standalone Weight-Loss Seeker | AOD-9604 as the primary driver of weight loss | The pivotal Phase 2b trial did not beat placebo. This is the wrong tool for that goal. | Poor Fit |
| Joint or Cartilage Support Interest | Off-label interest from animal osteoarthritis work | A single rabbit study. No human cartilage data at all. | Speculative |
| Athlete Subject to Anti-Doping Testing | Recovery or body-composition support during training | Growth hormone fragment, prohibited by WADA at all times. | Prohibited, Do Not Use |
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Section 03
How AOD-9604 Works
The mechanism, drawn almost entirely from animal studies, has three consistent pieces: it pushes fat cells to release and burn fat, it does this without engaging the growth hormone receptor, and it appears to lean on the beta-3 adrenergic system that governs fat breakdown.
Lipolysis Without the GH Receptor
In obese mice and Zucker rats, AOD-9604 increased fat oxidation and raised plasma glycerol, a marker of fat breakdown. Critically, it did not compete for the growth hormone receptor and did not trigger cell proliferation. The fat effect runs on a pathway separate from classic GH signaling.
Beta-3 Adrenergic Involvement
AOD-9604 raised the expression of the beta-3 adrenergic receptor, the main lipolytic receptor on fat cells, in obese mice. In beta-3 knockout mice, its chronic weight and lipolysis effects largely disappeared, pointing to that receptor as part of the route, though not the only one.
No Blood-Sugar Penalty
Unlike full growth hormone, which can raise blood glucose and blunt insulin, AOD-9604 did not worsen insulin sensitivity in the rodent studies. That cleaner metabolic profile was a major part of why it was advanced as a candidate.
A Narrow, Single-Purpose Signal
AOD-9604 does not raise IGF-1, build muscle, or produce broad growth effects. It carries one narrow instruction toward fat metabolism. That specificity is the design goal, and it is also why it produces no felt, dramatic effect.
Section 04
What the Evidence Shows
AOD-9604 is a case study in why preclinical promise does not always survive contact with a real trial. The animal record is strong and consistent. The pivotal human trial is the part the marketing tends to skip. Here is the actual record, in order.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| Ng 2000 (Horm Res) [1] | Preclinical, obese Zucker rats, oral 500 mcg/kg, 19 days | More than 50 percent reduction in body weight gain and increased adipose lipolysis, with no adverse effect on insulin sensitivity. | Foundational, Preclinical |
| Heffernan 2001 (Int J Obes) [2] | Preclinical, obese ob/ob mice, 14 days | Reduced body weight gain and increased fat oxidation. AOD9604 did not bind the GH receptor or induce cell proliferation. | Preclinical, Mechanistic |
| Heffernan 2001 (Endocrinology) [3] | Preclinical, obese mice and beta-3-AR knockout mice | Weight and lipolysis effects depended largely on the beta-3 adrenergic receptor; effects were lost in knockout mice. | Preclinical, Mechanistic |
| Wilding 2004 / Halford 2006 [4][5] | Reviews of the clinical-development program | Track AOD-9604 through Phase 2 obesity development as a human GH fragment that increases adipose breakdown. | Narrative Reviews |
| Phase 2b Obesity Trial (2007) | Randomized, double-blind, placebo-controlled, 534 subjects, 24 weeks | Did not produce clinically meaningful weight loss over placebo. Primary endpoint not met. Development halted. | Pivotal, Negative |
| Kwon 2015 (Ann Clin Lab Sci) [6] | Preclinical, rabbit knee osteoarthritis model, intra-articular | Intra-articular AOD9604, especially with hyaluronic acid, improved cartilage scores. Animal only, no human data. | Preclinical, Off-Topic |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 05
Realistic Expectations
AOD-9604 is a quiet compound with no felt effect and, in the definitive trial, no reliable scale effect on its own. If it has a place, it is as a small metabolic adjunct inside a plan that is already doing the heavy lifting through diet, training, or a GLP-1.
No Felt Effect
Expect to feel nothing notable. AOD-9604 acts on fat metabolism, not on receptors that produce a subjective sensation. The absence of an early effect is normal and tells you nothing about whether it is helping.
Adjunct Window
If there is any contribution, it shows up only as a small assist to a calorie deficit you are already running, not as standalone fat loss. Any visible change in this window is being driven mostly by your diet and training.
Course Window
The animal protocols and the human trials ran for weeks to months. Typical prescribed courses run 8 to 12 weeks. This is the window to judge honestly whether the broader plan is working, with AOD-9604 as a minor variable in it.
Decide With Your Prescriber
Because the human efficacy evidence is weak, the reassessment conversation matters. If your fat loss is tracking, it is largely your diet and training earning it. Decide with your prescriber whether continuing AOD-9604 is worth the cost.
Section 06
Dosing Protocol
Practical home dosing is a daily subcutaneous injection. Your RxPepsDirect physician sets the dose and course length. The figures below reflect both the trial context and the standard prescribed protocol.
| Context | Dose | Route / Frequency | Evidence Basis |
|---|---|---|---|
| Phase 2b Human Doses | Up to 1 mg/day | Oral, daily, 24 weeks | Did Not Beat Placebo |
| Rodent Lipolysis Studies | Weight-based | Oral or injected, daily, 14 to 19 days | Positive in Animals |
| RxPepsDirect Standard | 20 units (0.24 mg) | Subcutaneous, daily Monday to Friday | Clinical Practice |
| Cycle Pattern | 8 to 12 weeks on | Then 2 to 4 weeks off, per prescriber | Practice Convention |
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
The standard prescribed protocol is 20 units subcutaneous daily, Monday through Friday, where 20 units equals 0.2 mL at 1.2 mg/mL, delivering 0.24 mg per injection. Inject into abdominal fat with a standard insulin syringe and rotate sites. Note the gap between the small 0.24 mg daily practice dose and the up-to-1 mg daily oral doses used in the human trial that still failed: dose is not the reason the trial fell short, and pushing higher is not a fix your prescriber will chase blindly.
Section 07
Ready to Start
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 08
Safety and Side Effects
The one genuinely strong part of AOD-9604's human record is its safety. Across its trial program it was well tolerated, and unlike full growth hormone it did not raise blood sugar or worsen insulin sensitivity in the studies. The honest framing is that the safety data is reassuring while the efficacy data is not.
| Consideration | Detail | Action |
|---|---|---|
| Injection site reaction | Mild redness or irritation, the most commonly noted event | Rotate sites. Let the vial warm slightly before injecting. |
| Realistic efficacy expectation | Pivotal human trial did not beat placebo on weight | Treat it as an unproven adjunct, not a primary weight-loss tool. |
| Pregnancy / lactation | No safety data; catalog lists pregnancy as a contraindication | Avoid. |
| Anti-doping tested athletes | Growth hormone fragment, prohibited by WADA at all times | Do not use if subject to testing. Confirm with your governing body. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 09
Stacking
Pairs Well With
Semaglutide (GLP-1)
The evidence-backed weight-loss driver. AOD-9604 rides along as a speculative metabolic adjunct, with the GLP-1 doing the proven work.
BPC-157
Tissue repair through a different pathway. A common pairing when recovery and body-composition goals overlap. Separate injection windows.
CJC-1295 / Ipamorelin
A GH stack run at night while AOD-9604 targets fat metabolism. Complementary timing, different mechanisms.
Avoid or Use Caution
Lean Stack (already contains AOD-9604)
Do not run AOD-9604 alongside the combination Lean Stack vial, which already includes it. Stacking the same molecule twice adds cost, not benefit.
Anti-doping tested competition
AOD-9604 is a WADA-prohibited growth hormone fragment. Do not combine it with any training program subject to testing.
Pregnancy / lactation
No safety data. Avoid.
Section 10
Pricing
Pharmacy: Medication
$80 per 6 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted at 1.2 mg/mL, FedEx overnight.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including history review, contraindication screening, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Investigational Compound
Phase 2 evidence, no FDA approval
Off-Label, Legal Practice
Standard and legal in U.S. medicine
AOD-9604 is an investigational peptide. It reached Phase 2 obesity trials but was never FDA-approved for any indication, and its pivotal trial was negative. In the United States it is accessed through 503A patient-specific compounding under a physician prescription. Separately, AOD-9604 is a growth hormone fragment prohibited by the World Anti-Doping Agency at all times, so any athlete subject to testing should not use it. RxPepsDirect prescribers serve patients in 28 states.
Section 12
Community Q&A
Does AOD-9604 actually cause weight loss in humans?
The largest human trial says not reliably. The rodent data is convincing, but the developer's 534-subject Phase 2b obesity trial over 24 weeks did not show clinically meaningful weight loss over placebo, and the program was halted in 2007. It was never FDA-approved. Anyone calling it a proven human fat-loss drug is overstating the evidence.
Will it raise my IGF-1 or act like growth hormone?
No. AOD-9604 is the 176-191 fragment of growth hormone, the part tied to fat metabolism, without the rest. In the published work it did not bind the GH receptor, did not drive cell proliferation, and did not raise IGF-1. It is a narrow lipolytic signal, not a GH secretagogue.
Can athletes use it?
Treat it as off-limits if you are tested. WADA prohibits growth hormone fragments, and AOD-9604 falls under the non-approved substances category banned at all times. Confirm with your governing body, but the default for a tested athlete is that it is prohibited.
Why is it still available if the big trial failed?
Missing a Phase 2b endpoint means no FDA approval as an obesity drug. It does not make the molecule illegal. AOD-9604 has a long human safety record and remains available through 503A compounding under a prescription. The point to hold onto: a clean safety profile is not the same as proven efficacy.
How long is a course?
The standard prescribed protocol runs 8 to 12 weeks on, then 2 to 4 weeks off, with your prescriber reassessing before any repeat. Judge the result honestly: most of any fat loss in that window is being earned by your diet and training.
Section 13
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your AOD-9604 under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for contraindications, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
This guide states plainly that the pivotal Phase 2b obesity trial did not beat placebo, that there is no FDA approval, that the strong data is in rodents, and that AOD-9604 is WADA prohibited. We do not hide limitations to make a sale.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. PMID: 11146367
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. PMID: 11673763
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. PMID: 11713213
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004. PMID: 15134286
- Halford JCG. Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006. PMID: 16625817
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015. PMID: 26275694
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GLP-1 protocol guide
Microdose GLP-1: dosing math, evidence, and how to start safely in 2026
Microdosing semaglutide or tirzepatide means running them below the FDA-approved starter dose. The vial-duration math, the published evidence, and how to start with a provider.
NNMT inhibitor (metabolic weight-loss)
5-Amino-1MQ protocol guide: the NNMT inhibitor mechanism, the mouse data, and the missing human trial
A small-molecule NNMT inhibitor that raises cellular NAD+ to push fat cells toward burning energy. All weight evidence is preclinical mouse and cell-culture work. Honest that no human trial exists.
Lipotropic injection protocol
Lipotropic injections (Lipo-B / Lipo-C) protocol guide: what MIC, B12, and L-carnitine actually do, and the honest weight-loss evidence
MIC (methionine, inositol, choline) plus B12 or L-carnitine. The standalone fat-loss evidence is weak. These are adjuncts to diet and GLP-1 therapy, not primary weight-loss drugs.
Continue reading